Jelmyto single-dose KT(40MGX2)s
Ended Awarded
- Contract number
- SPE2DB25FWUXA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $151,765
Award facts
- Contract value 100% obligated
- $151,765.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $151,765.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jelmyto single-dose treatment (40mg x 2s). The contract, awarded on September 18, 2025, with an ultimate completion date of October 9, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency valued at $499.999 billion through November 2026, which authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting military healthcare facilities nationwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing contracts with the Defense Logistics Agency to deliver specialty medications and medical supplies to Department of Defense healthcare sites. The company's portfolio encompasses an extensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and specialty medications such as oncology treatments and injectable products. This delivery order for Jelmyto, a chemotherapy agent used in treatment of certain cancers, reflects the company's ongoing role in providing specialized pharmaceutical products to support military medical operations and healthcare delivery worldwide.
Quick answers
Who was awarded contract SPE2DB25FWUXA?
SPE2DB25FWUXA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 18, 2025.
How much is contract SPE2DB25FWUXA worth?
The government has obligated $151,765 on SPE2DB25FWUXA.
Is contract SPE2DB25FWUXA an order under another contract?
Yes. SPE2DB25FWUXA is a delivery order under SPE2DB25D9312, an indefinite delivery contract.
Was contract SPE2DB25FWUXA competed?
The extent of competition for SPE2DB25FWUXA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award